Catalyst Biosciences Revenue and Competitors

Location

$301.3M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Catalyst Biosciences's estimated annual revenue is currently $6k per year.(i)
  • Catalyst Biosciences received $115.0M in venture funding in February 2018.
  • Catalyst Biosciences's estimated revenue per employee is $333
  • Catalyst Biosciences's total funding is $301.3M.

Employee Data

  • Catalyst Biosciences has 18 Employees.(i)
  • Catalyst Biosciences grew their employee count by -14% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$4.4M57-8%$53MN/A
#2
$21.2M137-26%$110MN/A
#3
$1.1M70%N/AN/A
#4
$2.3M15150%N/AN/A
#5
$1.4M90%N/AN/A
#6
$11.5M74-12%N/AN/A
#7
$0.4M27510%$236.7MN/A
#8
$4M51-74%$160MN/A
#9
$2.5M1633%N/AN/A
#10
$3.3M21-12%N/AN/A
Add Company

Catalyst is focused on developing novel medicines to address serious medical conditions for patients who need new or better treatment options. We used a scientific approach focused on protease-based therapeutic candidates to build a clinical-stage biopharmaceutical company whose current mission is to develop valuable therapies for patients with hemophilia. Learn more about Our Hemophilia Program. A protease is an enzyme that cleaves target proteins. Learn more about Proteases.

keywords:Biotechnology,Cleantech,Healthcare,Pharmaceuticals,Wind Power

$301.3M

Total Funding

18

Number of Employees

$6k

Revenue (est)

-14%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Catalyst Biosciences News

2022-04-20 - -$0.56 Earnings Per Share Expected for Catalyst Biosciences, Inc ...

Wall Street analysts expect that Catalyst Biosciences, Inc. (NASDAQ:CBIO – Get Rating) will announce earnings per share (EPS) of ($0.56) for...

2022-03-30 - Catalyst Biosciences Reports Fourth Quarter and Year-end 2021 ...

SOUTH SAN FRANCISCO, Calif., March 31, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced its operating and...

2022-03-30 - Catalyst Biosciences Reports Fourth Quarter and Year-end 2021 ...

Catalyst is a research and clinical development biopharmaceutical company focused on developing protease therapeutics to address unmet medical...

2021-11-15 - Catalyst Biosciences : Investor presentation 4.7 MB

CATALYST BIOSCIENCES Corporate Overview 15 November 2021 © Catalyst Biosciences Forward looking statements Certain information contained in this presentation and statements made orally during this presentation include forward-looking statements that involve substantial risks and uncertainti ...

2021-09-28 - Catalyst Biosciences : Investor presentation 3.1 MB

Nasdaq: CBIO CATALYST BIOSCIENCES Corporate Overview 28 September 2021 CatalystBiosciences.com Forward looking statements Certain information contained in this presentation and statements made orally during this presentation include forward-looking statements that involve substantial risk ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$2.8M18-53%N/A
#2
$3.1M180%N/A
#3
$188M18-44%$127.8M
#4
$2.8M18-18%N/A
#5
$1.5M180%N/A

Catalyst Biosciences Funding

DateAmountRoundLead InvestorsReference
2004-10-29$10.3MASofinnova VeArticle
2006-02-10$30.0MBMorgenthaler VenturesArticle
2008-12-04$40.4MCEssex Woodlands Health VentureArticle
2012-01-09$7.0MUndisclosedPfizerArticle
2017-04-10$20.7MUndisclosedLadenburg Thalmann & Co. IncArticle
2017-12-22$10.5MUndisclosedJonesTrading Institutional Services LLCArticle
2018-02-14$115.0MUndisclosedJonesTrading Institutional Services LLCArticle